Drugs / Subgam
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01884311 | Aug 2015 → May 2017 | Bruton-type agammaglobulinemia, common variable immunodeficiency, hyper-IgM syndrome | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT02247141 | Jun 2000 → Jan 2005 | B cell deficiency | Bio Products Laboratory | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Subgam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02247141 ↗ |
| Modality | Protein / enzyme biologic | “this is a 16% subcutaneous IgG product” NCT01884311 ↗ |
| Route | Subcutaneous | “Subgam-VF will be administered subcutaneously using infusion pumps.” NCT01884311 ↗ |